Sanofi (NASDAQ:SNY) Shares Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 101.6% during the 1st quarter, Holdings Channel reports. The fund owned 70,732 shares of the company’s stock after acquiring an additional 35,644 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Sanofi were worth $3,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sanofi by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 257,655 shares of the company’s stock worth $12,427,000 after acquiring an additional 2,917 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after acquiring an additional 242 shares during the last quarter. Barclays PLC grew its holdings in shares of Sanofi by 58.3% in the 4th quarter. Barclays PLC now owns 1,012,927 shares of the company’s stock worth $48,853,000 after acquiring an additional 373,155 shares during the last quarter. Finally, Mariner LLC grew its holdings in shares of Sanofi by 8.0% in the 4th quarter. Mariner LLC now owns 108,997 shares of the company’s stock worth $5,257,000 after acquiring an additional 8,107 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Sanofi in a report on Tuesday, August 5th. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $62.00.

Sanofi Price Performance

SNY opened at $49.77 on Friday. The stock has a market cap of $122.21 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.17 and a beta of 0.48. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average price of $48.57 and a 200 day moving average price of $51.83.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.73 EPS. Analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.